Gritstone bio, Inc. (NASDAQ:GRTS) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. grew its position in shares of Gritstone bio, Inc. (NASDAQ:GRTS) by 4,598.5% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 553,150 shares of the company’s stock after buying an additional 541,377 shares during the period. Victory Capital Management Inc. owned about 0.51% of Gritstone bio worth $342,000 as of its most recent SEC filing.

Other large investors also recently bought and sold shares of the company. Artal Group S.A. acquired a new stake in shares of Gritstone bio during the 1st quarter valued at approximately $2,650,000. Vanguard Group Inc. lifted its position in shares of Gritstone bio by 7.2% in the 1st quarter. Vanguard Group Inc. now owns 4,733,791 shares of the company’s stock worth $12,166,000 after buying an additional 317,499 shares during the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of Gritstone bio in the 1st quarter valued at about $636,000. Forum Financial Management LP boosted its holdings in shares of Gritstone bio by 63.1% in the 2nd quarter. Forum Financial Management LP now owns 250,000 shares of the company’s stock valued at $154,000 after buying an additional 96,763 shares during the period. Finally, Klingman & Associates LLC bought a new stake in shares of Gritstone bio during the 1st quarter valued at about $89,000. Institutional investors own 48.46% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on GRTS shares. HC Wainwright restated a “buy” rating and issued a $4.00 target price on shares of Gritstone bio in a research note on Thursday, August 15th. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Gritstone bio in a research report on Monday, August 5th.

Gritstone bio Trading Down 7.4 %

Gritstone bio stock opened at $0.58 on Tuesday. Gritstone bio, Inc. has a 52-week low of $0.42 and a 52-week high of $3.33. The company has a quick ratio of 2.54, a current ratio of 2.54 and a debt-to-equity ratio of 1.83. The firm has a market capitalization of $63.08 million, a price-to-earnings ratio of -0.47 and a beta of 0.47. The firm has a 50-day moving average price of $0.55 and a two-hundred day moving average price of $0.92.

Gritstone bio (NASDAQ:GRTS) last issued its quarterly earnings data on Tuesday, August 13th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.28) by $0.12. The business had revenue of $0.92 million during the quarter, compared to analyst estimates of $2.77 million. Gritstone bio had a negative return on equity of 328.51% and a negative net margin of 910.50%. Sell-side analysts expect that Gritstone bio, Inc. will post -0.88 earnings per share for the current year.

Gritstone bio Company Profile

Gritstone bio, Inc, a clinical-stage biotechnology company, engages in developing vaccine-based immunotherapy candidates against cancer and infectious diseases. Its primary product candidate is GRANITE, an individualized immunotherapy candidate, which is in Phase 2/3 clinical trials for the treatment of microsatellite stable colorectal cancers; and has completed Phase 1/2 clinical trials for treating solid tumors.